Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Expands By 1,478.5%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,910,000 shares, a growth of 1,478.5% from the March 15th total of 121,000 shares. Approximately 11.6% of the shares of the stock are short sold. Based on an average trading volume of 2,810,000 shares, the short-interest ratio is presently 0.7 days.

Sensei Biotherapeutics Stock Up 3.4 %

SNSE traded up $0.01 during trading on Monday, hitting $0.38. The company’s stock had a trading volume of 305,573 shares, compared to its average volume of 923,604. The stock has a market capitalization of $9.64 million, a price-to-earnings ratio of -0.32 and a beta of 0.21. The firm’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.48. Sensei Biotherapeutics has a 12 month low of $0.25 and a 12 month high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, March 28th. The company reported ($0.27) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.27). On average, sell-side analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SNSE. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Friday, March 28th. Oppenheimer lifted their price target on shares of Sensei Biotherapeutics from $3.50 to $4.00 and gave the company an “outperform” rating in a report on Friday, March 28th.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd increased its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,903 shares of the company’s stock after purchasing an additional 48,977 shares during the period. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.